COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Top court sets out resolution model for novel plant variety dispute cases
- Favorable weather and mechanized ops aid wheat harvesting nationwide
- Rural vitalization: Live and empowering
- Foreign delegates gain a close look at grassroots livelihood, protection of people's rights
- Primary school students tell revolutionary stories of Jinggangshan in English
- Shanxi emergency official probed after deadly mine blast
